ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Mudumba, R. [1 ]
Nieva, J. J. [1 ]
Padula, W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE142
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK plus advanced non-small-cell lung cancer in France
    Sivignon, Marine
    Monnier, Remi
    Tehard, Bertrand
    Roze, Stephane
    PLOS ONE, 2020, 15 (01):
  • [32] Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinasepositive (ALK plus ) advanced non-small cell lung cancer in Thailand
    Sangroongruangsri, S.
    Kittrongsiri, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1556 - S1556
  • [33] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [34] The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective
    Cranmer, Holly
    Kearns, Isabella
    Young, Melanie
    Humphries, Michael J.
    Trueman, David
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 970 - 979
  • [35] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [36] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [37] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [38] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [39] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    LUNG CANCER, 2018, 124 : 248 - 254
  • [40] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Mu, Lifeng
    Zhou, Benhong
    ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
12345